Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03617003 · ClinicalTrials.gov registry record · Phase 1
Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03617003: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03617003 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03617003, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of a combination of the study drug called WST11 and PDT. Photodynamic therapy (PDT) is a type of ablation therapy (treatment which destroys tumor cells) which has been previously approved for the treatment of patients with other cancers. It works by using a drug that is given through the vein and then is activated in the tumor by light administered during endoscopy, which results in destruction of the cancer cells.
Interventions
- PROCEDURE Endoscopy
- DRUG WST11 mediated vascular targeted phototherapy (VTP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2025-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03617003
The ClinicalTrials.gov registry entry for NCT03617003 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Endoscopy is the first listed.
NCT03617003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03617003 about?
NCT03617003 is a clinical study titled "Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)". The purpose of this study is to test the safety of a combination of the study drug called WST11 and PDT. Photodynamic therapy (PDT) is a type of ablation therapy (treatment which destroys tumor cells) which has been previously approved for the treatment of patients with other cancers. It works by us...
What is the current status of trial NCT03617003?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-08-01. Estimated completion is 2025-07-15.
What interventions are being tested in trial NCT03617003?
The interventions under investigation include: Endoscopy (PROCEDURE), WST11 mediated vascular targeted phototherapy (VTP) (DRUG).
Who is sponsoring clinical trial NCT03617003?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.